Active	Status	Sponsor type	Region	Phase	Filter
22 Active 12 Inactive 34 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

14 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Galsky, Matthew
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2	Recruiting	3	700	Canada, US, RoW	disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin	Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC	Urothelial Carcinoma	06/26	04/29
HCRN GU 16-257, NCT03558087: Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing	Completed	2	76	US	Nivolumab, Opdivo, Gemcitabine, Gemzar, Cisplatin, Platinol	Matthew Galsky, Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai	Bladder Cancer	02/24	03/24
NCT03557918: Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer	Active, not recruiting	2	27	US	Tremelimumab	Matthew Galsky, AstraZeneca	Urothelial Carcinoma	02/22	04/23
NCT03448718: Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	Completed	2	19	US	Olaparib, Lynparza	Matthew Galsky, Icahn School of Medicine at Mount Sinai, AstraZeneca	Metastatic Urothelial Cancer	07/21	10/21
NCT03451331: Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer	Completed	2	49	US	Nivolumab, OPDIVO®, Gemcitabine, Gemzar, Carboplatin, Paraplatin®, Oxaliplatin, Eloxatin	Matthew Galsky, Bristol-Myers Squibb, Hoosier Cancer Research Network	Metastatic Urothelial Cancer	06/23	07/23
NCT05406713: Pembrolizumab in Muscle-invasive Bladder Cancer	Recruiting	2	46	US	Pembrolizumab, Keytruda	Matthew Galsky, Merck Sharp & Dohme LLC	Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma	06/24	06/24
SGNTUC-019, NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	Active, not recruiting	2	217	Europe, Japan, US, RoW	tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex	Seagen Inc.	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms	11/23	05/25
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2	Recruiting	2	332	Europe, Canada, Japan, US, RoW	disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®	Seagen Inc., Merck Sharp & Dohme LLC	Urothelial Carcinoma	10/24	03/26
DF1001-001, NCT04143711: Study of DF1001 in Patients With Advanced Solid Tumors	Recruiting	1/2	378	Europe, US	DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy	Dragonfly Therapeutics	Solid Tumor, Adult	10/26	12/26
FX-909-CLINPRO-1, NCT05929235: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma	Recruiting	1	75	US	FX-909	Flare Therapeutics Inc.	Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label	09/26	01/27
Friedlander
NCT03901573: High-Risk Skin Cancers With Atezolizumab Plus NT-I7	Terminated	1/2	31	US	NT-I7, efineptakin alfa, rhIL-7-hyFc, atezolizumab, Tecentriq	NeoImmuneTech, Immune Oncology Network	Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma	08/23	08/23
Vieira, Luciana
KITCHEN, NCT04301518: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs	Active, not recruiting	N/A	6500	US	Multimodal intervention strategy	Sera Prognostics, Inc., High Risk Pregnancy Center, Las Vegas, Nevada	Preterm Labor, Preterm Birth	12/23	12/26
Patel, Monica A
KITCHEN, NCT04301518: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs	Active, not recruiting	N/A	6500	US	Multimodal intervention strategy	Sera Prognostics, Inc., High Risk Pregnancy Center, Las Vegas, Nevada	Preterm Labor, Preterm Birth	12/23	12/26
Berkin, Jill
KITCHEN, NCT04301518: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs	Active, not recruiting	N/A	6500	US	Multimodal intervention strategy	Sera Prognostics, Inc., High Risk Pregnancy Center, Las Vegas, Nevada	Preterm Labor, Preterm Birth	12/23	12/26
Demattos, Lily
No trials found